{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:21:54Z","timestamp":1793467314159,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.seizure.2024.12.020","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T17:33:19Z","timestamp":1735752799000},"page":"118-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of antiseizure medications\u2014An overview of clinical data"],"prefix":"10.1016","volume":"125","author":[{"given":"Naina Mohamed Pakkir","family":"Maideen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnaveni","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-7800","authenticated-orcid":false,"given":"Rajkapoor","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda Thangadurai","family":"Subramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.seizure.2024.12.020_bib0001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.seizure.2024.12.020_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1167.2005.463007.x","article-title":"An introduction to antiepileptic drugs","volume":"46","author":"Perucca","year":"2005","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568026053386962","article-title":"Mechanisms of action of antiepileptic drugs","volume":"5","author":"Czapinski","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.seizure.2024.12.020_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0005","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/npr2.12196","article-title":"Neuropharmacology of antiseizure drugs","volume":"41","author":"Hakami","year":"2021","journal-title":"Neuropsychopharmacol Rep"},{"key":"10.1016\/j.seizure.2024.12.020_bib0006","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1111\/j.1528-1157.2000.tb01523.x","article-title":"Adverse effects of antiepileptic drugs","volume":"41","author":"Greenwood","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.12.020_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00002018-200023010-00003","article-title":"Adverse reactions to new anticonvulsant drugs","volume":"23","author":"Wong","year":"2000","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.seizure.2024.12.020_bib0008","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0009","unstructured":"United States Food and Drug Administration. Drug Safety and Availability. FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan). Available from https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr. Published on Nov 28, 2023. Accessed on Jan 23, 2024."},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1574886318666230505144014","article-title":"Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS syndromes-A narrative review","volume":"19","author":"Pakkir Maideen","year":"2024","journal-title":"Curr Drug Saf"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0011","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: Part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0012","unstructured":"United States Food and Drug Administration. Drug Safety and Availability. FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes. Available from https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-serious-skin-reactions-anti-seizure-drug-onfi-clobazam-and. Published on Dec 03, 2013. Accessed on Jan 23, 2024."},{"key":"10.1016\/j.seizure.2024.12.020_bib0013","unstructured":"National Pharmaceutical Regulatory Agency (NPRA). Ministry of Health Malaysia. Updates on Medication Safety Issues. Levetiracetam and Clobazam: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Available from https:\/\/www.npra.gov.my\/index.php\/en\/component\/content\/article\/454-english\/safety-alerts-main\/safety-alerts-2024\/1527606-levetiracetam-and-clobazam-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress.html. Published on Apr 29, 2024. Accessed on May 10, 2024."},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1665-2681(19)31663-1","article-title":"Severe acute hepatitis in the DRESS syndrome: report of two cases","volume":"9","author":"Lens","year":"2010","journal-title":"Ann Hepatol"},{"issue":"7-8","key":"10.1016\/j.seizure.2024.12.020_bib0015","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1345\/aph.1R084","article-title":"Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome","volume":"46","author":"G\u00f3mez-Zorrilla","year":"2012","journal-title":"Annal Pharmacother"},{"issue":"04","key":"10.1016\/j.seizure.2024.12.020_bib0016","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4236\/ojneph.2014.44022","article-title":"Levetiracetam-associated acute kidney injury and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"4","author":"Leblanc","year":"2014","journal-title":"Open J Nephrol"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/jdv.12346","article-title":"Dress syndrome induced by levetiracetam","volume":"29","author":"Eleni","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.seizure.2024.12.020_bib0018","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1002\/phar.1617","article-title":"Eosinophilia and fever with levetiracetam: a case report","volume":"35","author":"Flannery","year":"2015","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0019","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.jemermed.2015.10.004","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome induced by levetiracetam in a pediatric patient","volume":"50","author":"Bayram","year":"2016","journal-title":"J Emerg Med"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0019-5154.177777","article-title":"Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome","volume":"61","author":"Dar","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0021","first-page":"e4245","article-title":"A rare case of DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome with cholecystitis in a patient on levetiracetam","volume":"11","author":"Singh","year":"2019","journal-title":"Cureus"},{"issue":"19","key":"10.1016\/j.seizure.2024.12.020_bib0022","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.2169\/internalmedicine.8985-21","article-title":"Levetiracetam-induced hypersensitivity syndrome complicated by fulminant liver failure in a patient undergoing hemodialysis","volume":"61","author":"Sato","year":"2022","journal-title":"Internal Med"},{"key":"10.1016\/j.seizure.2024.12.020_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-1947-7-2","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case report","volume":"7","author":"Hall","year":"2013","journal-title":"J Med Case Rep"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0024","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"HLA"},{"key":"10.1016\/j.seizure.2024.12.020_bib0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.seizure.2019.02.011","article-title":"Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population","volume":"66","author":"Ihtisham","year":"2019","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0026","doi-asserted-by":"crossref","first-page":"89","DOI":"10.14581\/jer.16016","article-title":"Spectrum of cutaneous adverse reactions to levetiracetam and human leukocyte antigen typing in North-Indian patients","volume":"6","author":"Ramanujam","year":"2016","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.seizure.2024.12.020_bib0027","series-title":"Summary Safety Review \u2013 Clobazam-containing products \u2013 Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms","year":"2020"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0028","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/PEC.0000000000001754","article-title":"A drug reaction with eosinophilia and systemic symptoms syndrome associated with clobazam","volume":"36","author":"Manyas","year":"2020","journal-title":"Pediatr Emerg Care"},{"issue":"12","key":"10.1016\/j.seizure.2024.12.020_bib0029","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.18203\/2319-2003.ijbcp20205132","article-title":"DRESS syndrome due to clobazam: a case report","volume":"9","author":"Qureshi","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14740338.2023.2204227","article-title":"Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports","volume":"23","author":"An","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0032","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.18203\/2319-2003.ijbcp20191610","article-title":"Drug reaction with eosinophilia and systemic symptom induced by carbamazepine: a case report","volume":"8","author":"Damor","year":"2019","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0033","first-page":"339","article-title":"DRESS syndrome associated with carbamazepine and phenytoin","volume":"14","author":"Allam","year":"2004","journal-title":"European J Dermatol"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0034","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000086449","article-title":"Drug-induced hypersensitivity syndrome due to carbamazepine associated with reactivation of human herpesvirus 7","volume":"211","author":"Hara","year":"2005","journal-title":"Dermatology"},{"issue":"8","key":"10.1016\/j.seizure.2024.12.020_bib0035","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-4632.2008.03637.x","article-title":"Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review","volume":"47","author":"Ganeva","year":"2008","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0036","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1684\/ejd.2010.0887","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS): changing carbamazepine to phenobarbital-controlled epilepsy without the recurrence of DRESS","volume":"20","author":"Inadomi","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0037","article-title":"Drug-induced hypersensitivity syndrome caused by carbamazepine used for the treatment of trigeminal neuralgia","volume":"2016","author":"Ono","year":"2016","journal-title":"Case Rep Dent"},{"issue":"01","key":"10.1016\/j.seizure.2024.12.020_bib0038","doi-asserted-by":"crossref","first-page":"e6389","DOI":"10.5867\/medwave.2016.01.6389","article-title":"Skin reaction to carbamazepine or DRESS syndrome: a case presentation","volume":"16","author":"Cabrera Fundora","year":"2016","journal-title":"Medwave"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0039","first-page":"376","article-title":"Drug reaction with eosinophilia and systemic symptoms associated with carbamazepine (DRESS syndrome)\u2013case report and literature review","volume":"103","author":"Ociepa","year":"2016","journal-title":"Dermatol Rev\/Przegl\u0105d Dermatol"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0040","first-page":"1063","article-title":"Carbamazepine-induced DRESS syndrome: A case report","volume":"5","author":"Gancheva","year":"2017","journal-title":"J Pharmacol Clin Toxicol"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/ceji.2019.83700","article-title":"Carbamazepine-induced DRESS syndrome leading to reversible myocarditis in a child","volume":"44","author":"\u00c7etin","year":"2019","journal-title":"Central Eur J Immunol"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0042","doi-asserted-by":"crossref","first-page":"239","DOI":"10.22543\/7674.72.P239244","article-title":"Carbamazepine-induced DRESS syndrome: a case report","volume":"7","author":"Lazar","year":"2020","journal-title":"J Mind Med Sci"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0043","first-page":"2377","article-title":"Severe DRESS syndrome after carbamazepine intake in a case with multiple addictions: A case report","volume":"20","author":"Vrinceanu","year":"2020","journal-title":"Exp Ther Med"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0044","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/PRA.0000000000000619","article-title":"Carbamazepine-induced DRESS syndrome: a rare delayed hypersensitivity reaction","volume":"28","author":"Hou","year":"2022","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.9740\/mhc.2019.09.331","article-title":"Successful use of carbamazepine in a patient with drug rash with eosinophilia and systemic symptoms","volume":"9","author":"Bixby","year":"2019","journal-title":"Mental Health Clin"},{"key":"10.1016\/j.seizure.2024.12.020_bib0046","doi-asserted-by":"crossref","first-page":"9","DOI":"10.11604\/pamj.2014.18.9.3799","article-title":"Drug reaction with eosinophilia and systemic symptom (DRESS) induced by carbamazepine: a case report and literature review","volume":"18","author":"Omairi","year":"2014","journal-title":"Pan Afr Med J"},{"issue":"4","key":"10.1016\/j.seizure.2024.12.020_bib0047","first-page":"448","article-title":"Carbamazepine induced drug reaction with eosinophilia and Systemic symptoms syndrome","volume":"22","author":"Anaba","year":"2022","journal-title":"Nigerian Health J"},{"issue":"8","key":"10.1016\/j.seizure.2024.12.020_bib0048","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1111\/cts.13291","article-title":"Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis","volume":"15","author":"Biswas","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0049","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2013.10.003","article-title":"Genotype\u2013phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations","volume":"73","author":"Hsiao","year":"2014","journal-title":"J Dermatol Sci"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0050","article-title":"Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients","volume":"2018","author":"Sukasem","year":"2018","journal-title":"J Immunol Res"},{"issue":"7","key":"10.1016\/j.seizure.2024.12.020_bib0051","first-page":"16","article-title":"Association between HLA-B* 15: 02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study","volume":"20","author":"Kwan","year":"2014","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.seizure.2024.12.020_bib0052","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.seizure.2017.10.018","article-title":"HLA-A* 31: 01 and carbamazepine-induced DRESS syndrom in a sample of North African population","volume":"53","author":"Ksouda","year":"2017","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0053","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A* 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.seizure.2024.12.020_bib0054","first-page":"1134","article-title":"HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011"},{"key":"10.1016\/j.seizure.2024.12.020_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867490","article-title":"Implementation of HLA-B* 15: 02 genotyping as standard-of-care for reducing carbamazepine\/oxcarbazepine induced cutaneous adverse drug reactions in Thailand","volume":"13","author":"Tiwattanon","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0056","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4103\/0253-7613.84991","article-title":"DRESSing up to phenytoin","volume":"43","author":"Gude","year":"2011","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0057","first-page":"76","article-title":"Antiepileptic hypersensitivity and DRESS syndrome due to phenytoin in two pediatric cases","volume":"51","author":"Armin","year":"2009","journal-title":"Turkish J Pediatrics"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0058","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jaci.2004.12.438","article-title":"Phenytoin-induced dress syndrome: A case report","volume":"115","author":"Yazicioglu","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0059","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2230.2006.02202.x","article-title":"Phenytoin-induced DRESS with cross-reactivity to carbamazepine in a 10-year-old Indian child","volume":"31","author":"Mendiratta","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0060","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1081-1206(10)60273-6","article-title":"Phenytoin-induced DRESS","volume":"103","author":"Yazicioglu","year":"2009","journal-title":"Annal Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0061","first-page":"43","article-title":"Phenytoin-related DRESS syndrome in a hemodialysis patient","volume":"10","author":"Vlachopanos","year":"2012","journal-title":"BANTAO J"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0062","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jemermed.2011.05.052","article-title":"Phenytoin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a case report from the emergency department","volume":"44","author":"Oelze","year":"2013","journal-title":"J Emerg Med"},{"key":"10.1016\/j.seizure.2024.12.020_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-1947-7-2","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case report","volume":"7","author":"Hall","year":"2013","journal-title":"J Med Case Rep"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0064","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3126\/jnps.v35i1.10539","article-title":"Phenytoin induced drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"35","author":"Natt","year":"2015","journal-title":"J Nepal Paediatr Soc"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0065","doi-asserted-by":"crossref","first-page":"634","DOI":"10.5455\/njppp.2016.6.0614809062016","article-title":"Drug reaction with eosinophilia and systemic symptoms for phenytoin","volume":"6","author":"Chinnaiyan","year":"2016","journal-title":"Natl J Physiol Pharm Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0066","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1212\/NXG.0000000000000272","article-title":"DRESS after IV phenytoin associated with cytochrome P450 CYP2C9* 3 homozygosity","volume":"4","author":"Nissen","year":"2018","journal-title":"Neurol Genet"},{"issue":"Ek","key":"10.1016\/j.seizure.2024.12.020_bib0067","first-page":"159","article-title":"Phenytoin-associated DRESS syndrome: A Case Report Fenitoine Ba\u011fl\u0131 DRESS Sendromu: Olgu Sunumu","volume":"7","author":"Gen\u00e7eli","year":"2019","journal-title":"Pediatr Pract Res"},{"key":"10.1016\/j.seizure.2024.12.020_bib0068","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) caused by phenytoin","volume":"2017","author":"Riaz","year":"2017","journal-title":"Case Rep"},{"issue":"11","key":"10.1016\/j.seizure.2024.12.020_bib0069","first-page":"343","article-title":"Phenytoin induced drug reaction with eosinophilia and systemic symptoms (dress): case report","volume":"9","author":"Rodrigues","year":"2020","journal-title":"Case Rep Clin Med"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5530\/jyp.2022.14.48","article-title":"Phenytoin induced drug reaction with eosinophilia and systemic symptoms syndrome: a case report","volume":"14","author":"Gosi","year":"2022","journal-title":"J Young Pharmacists"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0071","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/08971900221116686","article-title":"Phenytoin induced drug reaction with eosinophilia and systemic symptoms syndrome: a clinical case report","volume":"37","author":"Varghese","year":"2024","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.seizure.2024.12.020_bib0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5935\/2236-5117.2022v59a315","article-title":"Evolution of DRESS syndrome related to phenytoin in a young woman","volume":"59","author":"Mikhael","year":"2022","journal-title":"Bras\u00edlia Med"},{"issue":"2-S","key":"10.1016\/j.seizure.2024.12.020_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22270\/jddt.v12i2-S.5416","article-title":"Phenytoin induced drug rash with eosinophilia and systemic symptoms: a rare paediatric case report","volume":"12","author":"Pattanshetti","year":"2022","journal-title":"J Drug Deliv Therapeut"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0074","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/pgs-2021-0126","article-title":"The association between HLA-B* 15: 02 and phenytoin-induced severe cutaneous adverse reactions: a meta-analysis","volume":"23","author":"Phung","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.seizure.2024.12.020_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106321","article-title":"Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children","volume":"162","author":"Manuyakorn","year":"2020","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0076","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.4979","article-title":"Genetic and clinical risk factors associated with phenytoin-induced cutaneous adverse drug reactions in Thai population","volume":"29","author":"Sukasem","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0077","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B* 15: 13 and HLA-B* 15: 02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenom J"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0078","first-page":"453","article-title":"Phenobarbital-induced DRESS: a lichenoid picture","volume":"13","author":"Chaabane","year":"2014","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0079","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2146\/ajhp120408","article-title":"Drug rash with eosinophilia and systemic symptoms syndrome associated with use of phenytoin, divalproex sodium, and phenobarbital","volume":"70","author":"Brizendine","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5455\/2319-2003.ijbcp20130620","article-title":"Phenobarbitone induced drug reaction with eosinophilia and systemic symptoms (DRESS): a case report","volume":"2","author":"Natt","year":"2017","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0081","doi-asserted-by":"crossref","first-page":"58","DOI":"10.17795\/jpr-5677","article-title":"Drug-induced hypersensitivity syndrome (DRESS) by phenobarbital-case report and literature review","volume":"4","author":"Nikkhah","year":"2016","journal-title":"J Pediatr Rev"},{"key":"10.1016\/j.seizure.2024.12.020_bib0082","doi-asserted-by":"crossref","DOI":"10.1177\/2333794X231216556","article-title":"Overlapping Stevens-Johnson Syndrome and DRESS syndrome caused by phenobarbital: a Vietnamese case report","author":"Van Nguyen","year":"2023","journal-title":"Glob Pediatr Health"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0083","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/pai.12058","article-title":"Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19* 2 in Thai children","volume":"24","author":"Manuyakorn","year":"2013","journal-title":"Pediatric Allergy Immunol"},{"issue":"10","key":"10.1016\/j.seizure.2024.12.020_bib0084","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/epi.13509","article-title":"Association of HLA genotypes with phenobarbital hypersensitivity in children","volume":"57","author":"Manuyakorn","year":"2016","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0085","doi-asserted-by":"crossref","DOI":"10.35248\/2684-124X.16.1.107","article-title":"Phenobarbitone causing drug reaction with eosinophilia and systemic symptoms (DRESS) in a Child previously exposed to long-term phenobarbitone as an infant","volume":"1","author":"Chong","year":"2016","journal-title":"Dermatol Case Report"},{"issue":"11","key":"10.1016\/j.seizure.2024.12.020_bib0086","first-page":"1424","article-title":"Dress syndrome related to phenobarbital use \u2013 Case report and literature review","volume":"4","author":"Jo\u00e3o","year":"2018","journal-title":"Open J Clin Med Case Rep"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0087","first-page":"85","article-title":"A case of valproic acid induced DRESS syndrome","volume":"50","author":"Kim","year":"2012","journal-title":"Korean J Dermatol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0088","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00296-010-1463-9","article-title":"DRESS syndrome with fatal results induced by sodium valproate in a patient with brucellosis and a positive cytoplasmic antineutrophilic cytoplasmic antibody test result","volume":"32","author":"Albayrak","year":"2012","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0089","first-page":"155","article-title":"Valproic acid-induced DRESS syndrome with acute liver failure","volume":"70","author":"Van Zoelen","year":"2012","journal-title":"Netherland J Medicine"},{"issue":"9","key":"10.1016\/j.seizure.2024.12.020_bib0090","doi-asserted-by":"crossref","first-page":"e36825","DOI":"10.5812\/ircmj.36825","article-title":"Drug reaction with eosinophilia and systemic symptoms induced by valproic acid: a case report","volume":"18","author":"Darban","year":"2016","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/j.seizure.2024.12.020_bib0091","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ebcr.2017.06.003","article-title":"Drug-induced hypersensitivity syndrome caused by valproic acid as a monotherapy for epilepsy: First case report in Asian population","volume":"8","author":"Wu","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.seizure.2024.12.020_bib0092","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajp.2017.05.015","article-title":"DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of Sodium Valproate and Olanzapine","volume":"28","author":"Penchilaiya","year":"2017","journal-title":"Asian J Psychiatr"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0093","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpsy.2020.03.003","article-title":"DRESS syndrome after lamotrigine and valproic acid use in a bipolar patient: a case report","volume":"34","author":"Afonso","year":"2020","journal-title":"Eur J Psychiatry"},{"issue":"4","key":"10.1016\/j.seizure.2024.12.020_bib0094","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4103\/psychiatry.IndianJPsychiatry_187_18","article-title":"Valproate-induced drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"60","author":"Dwivedi","year":"2018","journal-title":"Indian J Psychiatry"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5005\/jp-journals-10018-1298","article-title":"Valproate-induced drug rash eosinophilia with systemic symptoms syndrome: an unknown hepatotoxicity","volume":"9","author":"Gupta","year":"2019","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"Supplement 1","key":"10.1016\/j.seizure.2024.12.020_bib0096","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jcag\/gwz047.056","article-title":"A57 valproate induced dress syndrome causing mixed liver injury","volume":"3","author":"Schneider","year":"2020","journal-title":"J Can Assoc Gastroenterol"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0097","first-page":"e80","article-title":"Unay B. Valproic acid-induced DRESS in a child responding to cyclosporine with HLA analysis","volume":"120","author":"Ercan","year":"2022","journal-title":"Arch Argent Pediatr"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0098","doi-asserted-by":"crossref","first-page":"991","DOI":"10.18203\/2319-2003.ijbcp20202196","article-title":"A probable case of sodium valproate monotherapy induced drug reaction with eosinophilia and systemic symptoms syndrome: a case report in Indian population","volume":"9","author":"Arunnair","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0099","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/appi.ajp.161.3.579","article-title":"Valproic acid and hypersensitivity syndrome","volume":"161","author":"Roepke","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.seizure.2024.12.020_bib0100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1106423","article-title":"Case report: Progressive skin rash and lymphadenopathy associated with lamotrigine\u2212 valproic acid combination in a bipolar adolescent","volume":"14","author":"Duan","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0101","first-page":"35","article-title":"Valproate-related erythrodermia with reversible encephalopathy: a rare but serious adverse reaction, case report","volume":"23","author":"Rener-Primec","year":"2014","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0102","first-page":"23","article-title":"Lamotrigine Associated DRESS Syndrome\u2013a Case Report","volume":"7","author":"Balaban","year":"2009","journal-title":"Serb J Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1665-2681(19)31817-4","article-title":"Dress syndrome and fulminant hepatic failure induced by lamotrigine","volume":"8","author":"Amante","year":"2009","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.seizure.2024.12.020_bib0104","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1345\/aph.1P350","article-title":"First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis","volume":"44","author":"Roquin","year":"2010","journal-title":"Annals of Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0105","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4103\/0253-7613.103305","article-title":"Lamotrigine induced DRESS syndrome","volume":"44","author":"Naveen","year":"2012","journal-title":"Indian J Pharmacol"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0106","first-page":"236","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) in an adolescent treated with lamotrigine","volume":"18","author":"Ginory","year":"2013","journal-title":"J Pediatric Pharmacol Therapeut"},{"key":"10.1016\/j.seizure.2024.12.020_bib0107","article-title":"Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"2015","author":"Nathan","year":"2015","journal-title":"Case Reports"},{"key":"10.1016\/j.seizure.2024.12.020_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clineuro.2015.07.008","article-title":"Lamotrigine induced DIHS\/DRESS: Manifestations, treatment, and outcome in 57 patients","volume":"138","author":"Wang","year":"2015","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0109","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1002\/phar.1550","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by a lamotrigine\u2013ginseng drug interaction","volume":"35","author":"Myers","year":"2015","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"S1","key":"10.1016\/j.seizure.2024.12.020_bib0110","doi-asserted-by":"crossref","first-page":"S616","DOI":"10.1016\/j.eurpsy.2016.01.2304","article-title":"Lamotrigine induced DRESS syndrome in bipolar disorder: Multiple snares behind a potentially life-threatening adverse reaction","volume":"33","author":"Oriolo","year":"2016","journal-title":"European Psychiatry"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0111","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5021\/ad.2017.29.2.206","article-title":"Ahn KJ. Drug reaction with eosinophilia and systemic symptom syndrome induced by lamotrigine","volume":"29","author":"Han","year":"2017","journal-title":"Ann Dermatol"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0112","first-page":"1","article-title":"Possible DRESS syndrome in a patient with systemic sclerosis and rheumatoid arthritis during treatment with lamotrigine","volume":"10","author":"Jeremic","year":"2018","journal-title":"Arch Med (Oviedo)"},{"issue":"4","key":"10.1016\/j.seizure.2024.12.020_bib0113","first-page":"e7570","article-title":"Lamotrigine-induced DRESS syndrome manifesting as \u2018eosinophilic colitis\u2019: An uncommon presentation of a very uncommon condition","volume":"12","author":"Parsi","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0114","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13223-023-00848-6","article-title":"Fatal eosinophilic myocarditis and submassive hepatic necrosis in lamotrigine induced DRESS syndrome","volume":"19","author":"Doan","year":"2023","journal-title":"Allergy, Asthma Clin Immunology"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0115","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.4103\/jcsr.jcsr_119_22","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS): A report of two cases","volume":"12","author":"Rama","year":"2023","journal-title":"J Clin Scientific Res"},{"issue":"10","key":"10.1016\/j.seizure.2024.12.020_bib0116","article-title":"do C\u00e9u D\u00f3ria M. Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine","volume":"12","author":"Lameiras","year":"2019","journal-title":"BMJ Case Reports CP"},{"key":"10.1016\/j.seizure.2024.12.020_bib0117","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4168\/aard.2022.10.1.66","article-title":"DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome induced by lamotrigine in a child","author":"Kim","year":"2022","journal-title":"Allergy Asthma Respir Dis"},{"issue":"7","key":"10.1016\/j.seizure.2024.12.020_bib0118","first-page":"324","article-title":"DRESS is a mess: a case of cross reactivity between lacosamide and lamotrigine","volume":"74","author":"Packard","year":"2021","journal-title":"South Dakota Med"},{"issue":"Supplement 1","key":"10.1016\/j.seizure.2024.12.020_bib0119","first-page":"88","article-title":"Drug-induced hypersensitivity syndrome caused by lamotrigine, a case report","volume":"61","author":"Vrhovski","year":"2022","journal-title":"Acta Clin Croat"},{"key":"10.1016\/j.seizure.2024.12.020_bib0120","article-title":"Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection","volume":"2018","author":"Tawhari","year":"2018","journal-title":"Case Rep"},{"issue":"11","key":"10.1016\/j.seizure.2024.12.020_bib0121","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/children8111063","article-title":"Lamotrigine induced dress syndrome in a child: a case report and literature review","volume":"8","author":"Lin","year":"2021","journal-title":"Children"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0122","first-page":"680","article-title":"DRESS syndrome after lamotrigine use in a epilepsy patient: A case report","volume":"11","author":"Engin","year":"2021","journal-title":"Sakarya T\u0131p Dergisi"},{"key":"10.1016\/j.seizure.2024.12.020_bib0123","first-page":"1","article-title":"Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) masquerading as a systemic autoimmune process","volume":"2","author":"Shah","year":"2021","journal-title":"Front Med Case Rep"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0124","first-page":"19","article-title":"Case report: Lamotrigine-induced uncommon DRESS syndrome","volume":"14","author":"Gonz\u00e1lez","year":"2024","journal-title":"MOJ Clin Med Case Rep"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0125","first-page":"e22359","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine: a case report based literature review","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0126","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/1346-8138.14776","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs","volume":"46","author":"Tashiro","year":"2019","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0127","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/dtb.2019.229180rep","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine","volume":"58","author":"Lameiras","year":"2020","journal-title":"Drug Ther Bull"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0128","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v13i2.4541","article-title":"Severe cutaneous adverse reactions associated with high-dose lamotrigine for mood disorders: a case series","volume":"13","author":"Clark","year":"2022","journal-title":"Innov Pharm"},{"issue":"Supplement 1","key":"10.1016\/j.seizure.2024.12.020_bib0129","first-page":"88","article-title":"Drug-induced hypersensitivity syndrome caused by lamotrigine, a case report","volume":"61","author":"Vrhovski","year":"2022","journal-title":"Acta Clin Croat"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0019-5154.177784","article-title":"Lamotrigine-induced hypersensitivity syndrome with histologic features of CD30+ lymphoma","volume":"61","author":"Stephan","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"9","key":"10.1016\/j.seizure.2024.12.020_bib0131","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.arcped.2004.05.018","article-title":"Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver failure","volume":"11","author":"Bosdure","year":"2004","journal-title":"Arch Pediatr: Organe Off Soc Franc Pediatrie"},{"issue":"10","key":"10.1016\/j.seizure.2024.12.020_bib0132","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/15563650802342104","article-title":"Oxcarbazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"46","author":"D'Orazio","year":"2008","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0133","article-title":"Drug reaction with eosinophilia and systemic symptoms: DRESS following initiation of oxcarbazepine with elevated human herpesvirus-6 titer","volume":"2014","author":"Cornell","year":"2014","journal-title":"Case Rep Dermatol Med"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0134","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/0976-500X.189681","article-title":"Oxcarbazepine-induced drug rash with eosinophilia and systemic symptoms syndrome presenting as exfoliative dermatitis","volume":"7","author":"Saha","year":"2016","journal-title":"J Pharmacol Pharmacotherap"},{"issue":"2","key":"10.1016\/j.seizure.2024.12.020_bib0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.33192\/Smj.2020.23","article-title":"Association of oxcarbazepine-induced cutaneous adverse drug reactions with HLA-B* 15: 02 Allele","volume":"72","author":"Euasobhon","year":"2020","journal-title":"Siriraj Med J"},{"issue":"4","key":"10.1016\/j.seizure.2024.12.020_bib0136","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/8755122519850477","article-title":"Oxcarbazepine-induced cutaneous reaction in a female of Mexican ancestry","volume":"35","author":"Reinert","year":"2019","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0137","first-page":"1","article-title":"Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: a systematic review and meta-analysis","volume":"21","author":"Tangamornsuksan","year":"2018","journal-title":"J Pharm Pharmaceut Sci"},{"issue":"Supplement_5","key":"10.1016\/j.seizure.2024.12.020_bib0138","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1542\/peds.2017-1361","article-title":"HLA-A* 31: 01 and Oxcarbazepine-Induced DRESS in a patient with seizures and complete DCX deletion","volume":"141","author":"Kim","year":"2018","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0139","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/pgs-2017-0189","article-title":"Association between HLA-B* 15: 02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis","volume":"19","author":"Liu","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0140","doi-asserted-by":"crossref","first-page":"e28671","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.seizure.2024.12.020_bib0141","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00228-011-1005-8","article-title":"Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs","volume":"67","author":"Pereira de Silva","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0142","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol: Pract"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0143","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijd.IJD_582_17","article-title":"Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature","volume":"63","author":"De","year":"2018","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.seizure.2024.12.020_bib0144","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13671-021-00348-z","article-title":"Updates and insights in the diagnosis and management of DRESS syndrome","volume":"10","author":"Schunkert","year":"2021","journal-title":"Curr Dermatol Rep"},{"issue":"6","key":"10.1016\/j.seizure.2024.12.020_bib0145","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.clindermatol.2020.06.008","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"38","author":"Cardones","year":"2020","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.seizure.2024.12.020_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: A literature review and treatment algorithm","volume":"16","author":"Calle","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.seizure.2024.12.020_bib0147","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","article-title":"Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis","volume":"10","author":"Hama","year":"2022","journal-title":"J Allergy Clin Immunol: Pract"},{"key":"10.1016\/j.seizure.2024.12.020_bib0148","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/S0365-05962012000300013","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS)\/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts","volume":"87","author":"Criado","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.seizure.2024.12.020_bib0149","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijd.IJD_582_17","article-title":"Drug reaction with eosinophilia and systemic symptoms: an update and review of recent literature","volume":"63","author":"De","year":"2018","journal-title":"Indian J Dermatol"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124003571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124003571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T15:10:20Z","timestamp":1769958620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131124003571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":149,"alternative-id":["S1059131124003571"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2024.12.020","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of antiseizure medications\u2014An overview of clinical data","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2024.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}